Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-1-2
pubmed:abstractText
Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
689-94
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:14512299-B-Cell Activation Factor Receptor, pubmed-meshheading:14512299-B-Cell Maturation Antigen, pubmed-meshheading:14512299-B-Lymphocytes, pubmed-meshheading:14512299-Base Sequence, pubmed-meshheading:14512299-Bone Marrow Cells, pubmed-meshheading:14512299-Cell Division, pubmed-meshheading:14512299-Cell Survival, pubmed-meshheading:14512299-DNA Primers, pubmed-meshheading:14512299-Humans, pubmed-meshheading:14512299-Immunohistochemistry, pubmed-meshheading:14512299-Leukocytes, Mononuclear, pubmed-meshheading:14512299-Membrane Proteins, pubmed-meshheading:14512299-Multiple Myeloma, pubmed-meshheading:14512299-Polymerase Chain Reaction, pubmed-meshheading:14512299-Receptors, Tumor Necrosis Factor, pubmed-meshheading:14512299-Reference Values, pubmed-meshheading:14512299-Transmembrane Activator and CAML Interactor Protein, pubmed-meshheading:14512299-Tumor Cells, Cultured
pubmed:year
2004
pubmed:articleTitle
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
pubmed:affiliation
Department of Immunology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905. jelinek.diane@mayo.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.